WISeR Model: Implications for Wound Care Clinicians

Key Clinical Takeaways

• 1. WISER Model Launch: AI-Driven Prior Authorization for Wound Care
  Beginning January 2026, CMS will pilot the WISER Model in six states—New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington—focusing on skin substitutes. The initiative uses artificial intelligence with clinician oversight to streamline prior authorization, reduce fraud and waste, and improve Medicare payment accuracy.

• Documentation and Compliance Are Key to Success
  Clinicians in participating states should strengthen documentation to align with local and national coverage determinations (LCD/NCD) for skin substitute applications. Practices with consistent, evidence-based documentation may earn “Gold Card” status, allowing them to bypass prior authorization entirely.

• Preparing Practices for AI-Enhanced Care Review
  Providers should train staff on efficient submission workflows, ensure timely and accurate prior authorization requests, and monitor compliance metrics. Engagement with CMS feedback loops will help shape future iterations of the program—potentially expanding review to include debridement and negative pressure wound therapy.
   

Transcript

Please note: This content is a direct transcript, capturing the authentic conversation without edits. Some language may reflect the flow of live discussion rather than polished text. 

What we’re going to talk about today is the WISeR model and its implications for wound care clinicians. This is an educational overview of what this model looks like and what physicians need to be prepared for. 

The WISeR model was started and envisioned by CMS mainly to protect American taxpayers by using artificial intelligence and machine learning, combined with human clinical review, to ensure appropriate Medicare payment for selected items and services.

CMS considers this a voluntary model intended to encourage care navigation and promote safe, evidence-supported best practices for treating people with Medicare. WISeR will run for six years in six states: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. For wound care clinicians, the primary service selected is skin substitutes.

The application period for technology vendors was open until January 27, 2025. CMS selected companies capable of implementing this model. The reason WISeR was implemented—and why skin substitutes were specifically selected—was discussed by Dr. Oz at the AMA meeting, which I had the privilege to attend. His comments provided insight into why this model was created and why skin substitutes will be under review for the next six years in these states.

This is part of a CMS Innovation Center initiative testing a technology-driven prior authorization model. The goal is to empower physician practices, streamline care delivery, and reduce administrative burden. The focus is on non-routine, non-emergent services under traditional Medicare. The model incorporates AI, but not AI alone—there is promised clinician oversight to ensure appropriate care delivery.

The four main goals are:

    1.    Focus healthcare spending on services that improve patient well-being

    2.    Increase transparency of existing Medicare coverage policies

    3.    Apply commercial payer processes that may be faster, easier, and more accurate

    4.    Reduce the use of medically unnecessary care

As discussed by Dr. Oz, there is significant waste in healthcare—estimated to be as much as 25% of U.S. healthcare spending. Some services have limited clinical evidence of effectiveness, may not align with individual patient needs, and can lead to complications and further unnecessary services.

The solution CMS proposes is to reduce clinically unsupported care by working with technology companies that can enhance and expedite the review process for a pre-selected set of services vulnerable to fraud, waste, and abuse. That is why WISeR was created.

At its core, this is a new form of prior authorization. CMS is using this model for costly services where there is concern about waste and abuse. The goal is to empower patients to partner with their healthcare providers on the most clinically appropriate care plan, protect taxpayers, and focus provider efforts on care that most improves patient well-being.

From what I heard at the AMA webinar and from Dr. Oz, this could become a model for the future. Many physicians experience burnout from traditional prior authorization processes common in commercial insurance, which can delay or deny care and harm patients. CMS wants to test whether a technology-based model can reduce waste and abuse while delivering faster decisions and minimizing delays for appropriate care.

The intent is to promote evidence-based prevention and appropriate use of services while reducing unnecessary tests.

For wound care practitioners, the key service under WISeR will be skin and tissue substitutes. This applies to all physicians in the selected pilot states. Technology vendors must respond to prior authorization requests within 72 hours, providing either approval or reasons why the request does not meet CMS guidelines.

If an AI system issues a non-affirmation decision, it must be reviewed by a qualified clinician with relevant expertise. CMS will evaluate savings, accuracy, and physician experience metrics. Vendors will be held accountable for inappropriate denials and must meet performance standards.

This model also introduces the opportunity for “Gold Card” status. Physicians who consistently provide evidence-based, compliant, and accurate documentation may bypass prior authorization altogether. This is expected to launch around mid-2026, with periodic monitoring to encourage trust and accountability between CMS and clinicians.

It’s important to remember that AI does not replace physician review. All adverse or non-affirmation decisions are reviewed by qualified clinicians. Vendors must meet strict standards for privacy, security, and timeliness and will be continuously monitored to ensure patient safety and fairness.

Currently, WISeR is limited to skin substitutes. However, if successful, it may expand to other services such as debridement and negative pressure wound therapy. The goal is to reduce waste and abuse while providing faster, standardized authorization to minimize treatment delays.

Gold carding is the ideal outcome. Physicians with excellent documentation and compliance will not need frequent prior authorization, but this requires consistent adherence to evidence-based wound management protocols.

Key takeaways for clinicians include maintaining robust clinical documentation aligned with LCDs and NCDs for skin substitutes. Practices should use checklists to ensure patients qualify, document standard wound management attempts, confirm lack of response to conservative care, and apply correct diagnoses.

Clinicians in the six pilot states should expect WISeR prior authorization to apply. Monitor compliance metrics closely, as accuracy and timeliness matter. Engage with CMS feedback mechanisms—this is a pilot, and CMS wants to learn from clinician experience to ensure patient care is not harmed by delays.

Common questions include:

    •    Will WISeR change Medicare payment rates? No. There are no changes to payment or coverage.

    •    Are physicians required to participate? No, but all claims in pilot areas will be reviewed.

    •    Can denials be appealed? Yes, using existing Medicare appeal rights.

    •    Is expedited review available? Yes, urgent cases can be reviewed within 48 hours.

Technology vendors will also be evaluated on response times, appeal rates, and physician experience. Aggregate results will be publicly reported, but individual clinician names will not be disclosed. Vendors may face penalties for inappropriate denials.

CMS’s goal is to balance efficiency and access. Wound care practices should train staff on efficient submission workflows, ensure high-quality documentation, select appropriate patients using evidence-based criteria, and stay informed on CMS updates through professional societies.

WISeR has the potential to be a positive step toward smarter, less burdensome care delivery. Some clinicians see value in upfront review to prevent future denials or clawbacks. Hopefully, this model will benefit physicians, clinicians, and patients. If issues arise, it’s essential to communicate feedback to CMS.

Thank you for listening.